Clinical Trials Browser

INDUSTRY × Neuroendocrine Tumors × Nivolumab × Clear all

NCT05266612 2024-08-09

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Phase 1 Recruiting

Neuroendocrine Tumors